Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Theravance Biopharma R&D IP LLC has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units, indicating that each active case has a separate examination setting.
VALENROD, YEVGENY is the busiest examiner, with 1 pending matter. Because no examiner or art unit contains multiple pending matters, centralized docket control should be paired with individualized claim and response analysis.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 1 | 72.6% | +25.0% |
| WARD, PAUL V | 1 | 83.3% | -12.2% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18496404 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18127570 | METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY | WESTERBERG, NISSA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443907 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | VALENROD, YEVGENY | — |
| 18127570 | METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY | WESTERBERG, NISSA M | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1622 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443907 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | VALENROD, YEVGENY | 1628 | DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18496404 | PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME | WARD, PAUL V | 1622 | §102 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18127570 | METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY | WESTERBERG, NISSA M | 1618 | §103Other | Final Rejection | — | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTheravance Biopharma R&D IP LLC has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Yevgeny Valenrod has the most, with 1 of Theravance Biopharma R&D IP LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.